Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016

Publication ID: GMD1116073
Publication Date: November 30, 2016
Pages: 477
Publisher: Global Markets Direct
Countries: Global

$2,000.00

Publication License Type *

- SINGLE USER LICENSE (PDF), $2,000.00
- SITE LICENSE (PDF), $4,000.00
- GLOBAL LICENSE (PDF), $6,000.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Description:

Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides an overview of the Refractory Acute Myeloid Leukemia (Oncology) pipeline landscape.

The acute myeloid leukemia cells which resist treatment are referred to as refractory acute myeloid leukemia. Signs and symptoms includes pale skin, swollen gums, minor infections, such as perianal sores, loss of appetite and weight loss and aches or discomfort in bones or joints such as knees, hips or shoulders. Predisposing factors include age, history of other blood cancers or disorders, genetic disorder and past chemotherapy or radiation treatments. Treatment options include drugs not already used during past treatment and conditioning therapy followed by transplantation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Refractory Acute Myeloid Leukemia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Acute Myeloid Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Refractory Acute Myeloid Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Acute Myeloid Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 34, 39, 1, 3, 4 and 1
respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 6 and 1 molecules, respectively. Refractory Acute Myeloid Leukemia.

Refractory Acute Myeloid Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Acute Myeloid Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Refractory Acute Myeloid Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Refractory Acute Myeloid Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Acute Myeloid Leukemia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Refractory
Acute Myeloid Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Refractory Acute Myeloid Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

**Table Of Contents:**

Table of Contents
Table of Contents 2
Introduction 6
Refractory Acute Myeloid Leukemia Overview 7
Therapeutics Development 8
Refractory Acute Myeloid Leukemia - Therapeutics under Development by Companies 10
Refractory Acute Myeloid Leukemia - Therapeutics under Investigation by Universities/Institutes 14
Refractory Acute Myeloid Leukemia - Pipeline Products Glance 15
Refractory Acute Myeloid Leukemia - Products under Development by Companies 18
Refractory Acute Myeloid Leukemia - Products under Investigation by Universities/Institutes 24
Refractory Acute Myeloid Leukemia - Companies Involved in Therapeutics Development 25
Refractory Acute Myeloid Leukemia - Therapeutics Assessment 85
Drug Profiles 107
Refractory Acute Myeloid Leukemia - Dormant Projects 448
Refractory Acute Myeloid Leukemia - Discontinued Products 451
Refractory Acute Myeloid Leukemia - Product Development Milestones 452
Appendix 465

List of Tables
Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016 19
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Development, H2 2016 28
Products under Development by Companies, H2 2016 29
Products under Development by Companies, H2 2016 (Contd..1) 30
Products under Development by Companies, H2 2016 (Contd..2) 31
Products under Development by Companies, H2 2016 (Contd..3) 32
Products under Development by Companies, H2 2016 (Contd..4) 33
Products under Development by Companies, H2 2016 (Contd..5) 34
Products under Investigation by Universities/Institutes, H2 2016 35
Refractory Acute Myeloid Leukemia - Pipeline by 4SC AG, H2 2016 36
Refractory Acute Myeloid Leukemia - Pipeline by AbbVie Inc, H2 2016 37
Refractory Acute Myeloid Leukemia - Pipeline by Actinium Pharmaceuticals Inc, H2 2016 38
Refractory Acute Myeloid Leukemia - Pipeline by AEGLEA BioTherapeutics Inc, H2 2016 40
Refractory Acute Myeloid Leukemia - Pipeline by Agios Pharmaceuticals Inc, H2 2016 41
Refractory Acute Myeloid Leukemia - Pipeline by Aileron Therapeutics Inc, H2 2016 42
Refractory Acute Myeloid Leukemia - Pipeline by Amgen Inc, H2 2016 43
Refractory Acute Myeloid Leukemia - Pipeline by Arog Pharmaceuticals Inc, H2 2016 44
Refractory Acute Myeloid Leukemia - Pipeline by Array BioPharma Inc, H2 2016 45
Refractory Acute Myeloid Leukemia - Pipeline by Astellas Pharma Inc, H2 2016 46
Refractory Acute Myeloid Leukemia - Pipeline by AstraZeneca Plc, H2 2016 47
Refractory Acute Myeloid Leukemia - Pipeline by AVEO Pharmaceuticals Inc, H2 2016 48
Refractory Acute Myeloid Leukemia - Pipeline by Bellicum Pharmaceuticals Inc, H2 2016 49
Refractory Acute Myeloid Leukemia - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 50
Refractory Acute Myeloid Leukemia - Pipeline by BioLineRx Ltd, H2 2016 51
Refractory Acute Myeloid Leukemia - Pipeline by BioSight Ltd, H2 2016 52
Refractory Acute Myeloid Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2016 53
Refractory Acute Myeloid Leukemia - Pipeline by Boston Biomedical Inc, H2 2016 54
Refractory Acute Myeloid Leukemia - Pipeline by Bristol-Myers Squibb Company, H2 2016 55
Refractory Acute Myeloid Leukemia - Pipeline by Calithera Biosciences Inc, H2 2016 56
Refractory Acute Myeloid Leukemia - Pipeline by Celgene Corp, H2 2016 57
Refractory Acute Myeloid Leukemia - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 58
Refractory Acute Myeloid Leukemia - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016 59
Refractory Acute Myeloid Leukemia - Pipeline by CTI BioPharma Corp, H2 2016 60
Refractory Acute Myeloid Leukemia - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 61
Refractory Acute Myeloid Leukemia - Pipeline by Eisai Co Ltd, H2 2016 62
Refractory Acute Myeloid Leukemia - Pipeline by Eli Lilly and Company, H2 2016 63
Refractory Acute Myeloid Leukemia - Pipeline by EpiZyme Inc, H2 2016 64
Refractory Acute Myeloid Leukemia - Pipeline by Exelixis Inc, H2 2016 65
Refractory Acute Myeloid Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 66
Refractory Acute Myeloid Leukemia - Pipeline by Fate Therapeutics Inc, H2 2016 67
Refractory Acute Myeloid Leukemia - Pipeline by FLX Bio, Inc., H2 2016 68
Refractory Acute Myeloid Leukemia - Pipeline by FORMA Therapeutics Inc, H2 2016 69
Refractory Acute Myeloid Leukemia - Pipeline by Fujifilm Corp, H2 2016 70
Refractory Acute Myeloid Leukemia - Pipeline by GlaxoSmithKline Plc, H2 2016 71
Refractory Acute Myeloid Leukemia - Pipeline by GlycoMimetics Inc, H2 2016 72
Refractory Acute Myeloid Leukemia - Pipeline by Igenica Biotherapeutics Inc, H2 2016 73
Refractory Acute Myeloid Leukemia - Pipeline by Incyte Corp, H2 2016 74
Refractory Acute Myeloid Leukemia - Pipeline by Io Therapeutics Inc, H2 2016 75
Refractory Acute Myeloid Leukemia - Pipeline by JW Pharmaceutical Corp, H2 2016 76
Refractory Acute Myeloid Leukemia - Pipeline by Karyopharm Therapeutics Inc, H2 2016 77
Refractory Acute Myeloid Leukemia - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016 78
Refractory Acute Myeloid Leukemia - Pipeline by MacroGenics Inc, H2 2016 79
Refractory Acute Myeloid Leukemia - Pipeline by Merck & Co Inc, H2 2016 80
Refractory Acute Myeloid Leukemia - Pipeline by Merck KGaA, H2 2016 81
Refractory Acute Myeloid Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 82
Refractory Acute Myeloid Leukemia - Pipeline by NantKwest Inc, H2 2016 83
Refractory Acute Myeloid Leukemia - Pipeline by Novartis AG, H2 2016 84
Refractory Acute Myeloid Leukemia - Pipeline by Oxford BioTherapeutics Ltd, H2 2016 85
Refractory Acute Myeloid Leukemia - Pipeline by Pfizer Inc, H2 2016 86
Refractory Acute Myeloid Leukemia - Pipeline by Pharma Mar SA, H2 2016 87
Refractory Acute Myeloid Leukemia - Pipeline by Polaris Pharmaceuticals Inc, H2 2016 88
Refractory Acute Myeloid Leukemia - Pipeline by Seattle Genetics Inc, H2 2016 89
Refractory Acute Myeloid Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H2 2016 90
Refractory Acute Myeloid Leukemia - Pipeline by TaiGen Biotechnology Co Ltd, H2 2016 91
Refractory Acute Myeloid Leukemia - Pipeline by Tolero Pharmaceuticals Inc, H2 2016 92
Refractory Acute Myeloid Leukemia - Pipeline by Tragara Pharmaceuticals Inc, H2 2016 93
Refractory Acute Myeloid Leukemia - Pipeline by VioQuest Pharmaceuticals Inc, H2 2016 94
Refractory Acute Myeloid Leukemia - Pipeline by ZIOPHARM Oncology Inc, H2 2016 95
Assessment by Monotherapy Products, H2 2016 96
Assessment by Combination Products, H2 2016 97
Number of Products by Stage and Target, H2 2016 99
Number of Products by Stage and Mechanism of Action, H2 2016 107
Number of Products by Stage and Route of Administration, H2 2016 115
Number of Products by Stage and Molecule Type, H2 2016 117
Refractory Acute Myeloid Leukemia - Dormant Projects, H2 2016 459
Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..1), H2 2016 460
Refractory Acute Myeloid Leukemia - Dormant Projects (Contd..2), H2 2016 461
Refractory Acute Myeloid Leukemia - Discontinued Products, H2 2016 462

List of Figures
Number of Products under Development for Refractory Acute Myeloid Leukemia, H2 2016 19
Number of Products under Development for Refractory Acute Myeloid Leukemia - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 26
Comparative Analysis by Clinical Stage Development, H2 2016 27
Comparative Analysis by Early Stage Products, H2 2016 28
Assessment by Monotherapy Products, H2 2016 96
Number of Products by Top 10 Targets, H2 2016 98
Number of Products by Stage and Top 10 Targets, H2 2016 98
Number of Products by Top 10 Mechanism of Actions, H2 2016 106
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 106
Number of Products by Routes of Administration, H2 2016 114
Number of Products by Stage and Routes of Administration, H2 2016 114
Number of Products by Molecule Types, H2 2016 116
Number of Products by Stage and Molecule Types, H2 2016 116

Companies Mentioned:

4SC AG
AbbVie Inc
Actinium Pharmaceuticals Inc
ADC Therapeutics Sarl
Aeglea BioTherapeutics Inc
Agios Pharmaceuticals Inc
Aileron Therapeutics Inc
Amgen Inc
Arog Pharmaceuticals Inc
Array BioPharma Inc
Astellas Pharma Inc
AstraZeneca Plc
AVEO Pharmaceuticals Inc
Bellicum Pharmaceuticals Inc
Bio-Cancer Treatment International Ltd
BioLineRx Ltd
BioSight Ltd
Boehringer Ingelheim GmbH
Boston Biomedical Inc
Bristol-Myers Squibb Company
Calithera Biosciences Inc
Celgene Corp
Cornerstone Pharmaceuticals Inc
CSPC Pharmaceutical Group Limited
CTI BioPharma Corp
Daiichi Sankyo Company Ltd
Eisai Co Ltd
Eli Lilly and Company
EpiZyme Inc
Exelixis Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
FLX Bio, Inc.
FORMA Therapeutics Inc
Fujifilm Corp
GlaxoSmithKline Plc
GlycoMimetics Inc
Igenica Biotherapeutics Inc
Iincyte Corp
Io Therapeutics Inc
JW Pharmaceutical Corp
Karyopharm Therapeutics Inc
Kyowa Hakko Kirin Co Ltd
MacroGenics Inc
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
NantKwest Inc
Novartis AG
Oxford BioTherapeutics Ltd
Pfizer Inc
Pharma Mar SA
Polaris Pharmaceuticals Inc
Seattle Genetics Inc
Sunesis Pharmaceuticals Inc
TaiGen Biotechnology Co Ltd
Tolero Pharmaceuticals Inc
Tragara Pharmaceuticals Inc
License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Global License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Global License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
*If Applicable.


Links